TOKYO--(BUSINESS WIRE)--Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced that Mayo Clinic in

Phoenix, AZ began treating patients with its advanced PROBEAT-V proton

therapy system on March 14.

The PROBEAT-V is a state-of-the-art proton beam therapy system used to

deliver Hitachi’s Discrete Spot Scanning capability to each treatment

room. The 190 degree half gantries provide efficient yet spacious

treatment room environments. Hitachi’s smallest treatment spot size to

date enables the system to achieve highly precise treatments.

Mayo Clinic in Rochester, Minnesota is also equipped with an identical

proton therapy system and has been treating patients since June, 2015.

Mayo Clinic treats more than 1.3 million patients annually from all 50

states and 143 countries. Mayo Clinic has maintained its position as one

of the top hospitals in U.S. News & World Report rankings for more than

20 years.

Hitachi has now supplied proton therapy systems for four centers in the

United States, with a fifth system currently under construction.

Given the growing demand for technical and clinical advancements in the

treatment of cancer, interest in proton therapy is on the rise, with

more and more hospitals and cancer treatment facilities venturing into

this area. Hitachi will continue to globally expand the healthcare

business where proton therapy is its flagship solution, and contribute

to cancer treatment around the world.

Details of the PROBEAT-V System can be found at the following link:

Overview of Proton Beam Therapy

Proton Beam Therapy (PBT) is an advanced form of external beam

radiotherapy. Protons from hydrogen atoms are extracted and accelerated

up to 70% the speed of light. Its energy is concentrated directly on the

tumor while avoiding radiation dose to the surrounding healthy tissues.

PBT improves the quality of life for cancer patients since the patient

experiences no pain during treatment and the procedure has very few side

effects compared with that of traditional radiotherapy. In most cases,

patients can continue with their normal daily activities while

undergoing treatment. Because there are fewer side effects, PBT is

expected to expand, especially for pediatric treatment.

Overview of Spot-Scanning Irradiation Technology

Spot-scanning irradiation technology does not scatter proton beams as

with conventional proton beam therapy. Rather, it repeatedly turns a

narrow proton beam on and off at high speed as it progressively changes

location to irradiate entire tumor volumes. Protons can be aimed with

high precision according to the targeted tumors, even those with complex

shapes, while minimizing the impact on nearby healthy tissue.

Furthermore, customized equipment such as collimators and boluses are

not required.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers

innovations that answer society’s challenges with our talented team and

proven experience in global markets. The company’s consolidated revenues

for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3

billion). Hitachi is focusing more than ever on the Social Innovation

Business, which includes power & infrastructure systems, information &

telecommunication systems, construction machinery, high functional

materials & components, automotive systems, healthcare and others. For

more information on Hitachi, please visit the company's website at http://www.hitachi.com.

Contacts

U.S.:

Hitachi America, Ltd.

Tamie Nagamoto, +1-914-333-2987

or

Japan:

Hitachi,

Ltd.

Scott Shi, +81-3-5208-9324